Drugmaker Pfizer presented its oral COVID-19 antiviral clinical candidate PF-07321332 last week at ACS Spring 2021. The compound, which is currently in Phase 1 clinical trials, is the first orally ...
No takes yet. Share an insight, caveat, or question.
Bethany A. Halford (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: